DPP‐4/SGLT2 inhibitor combined therapy for type 2 diabetes
Sign Up to like & getrecommendations! Published in 2017 at "Prescriber"
DOI: 10.1002/psb.1626
Abstract: DPP‐4 inhibitors and SGLT2 inhibitors lower blood glucose by complementary mechanisms of action, and two fixed‐dose combinations – Qtern and Glyxambi – have now been approved for the treatment of type 2 diabetes. This article… read more here.
Keywords: inhibitor combined; dpp sglt2; sglt2 inhibitor; combined therapy ... See more keywords
Exploring the clinical utility of DPP-IV and SGLT2 inhibitors in papillary thyroid cancer: a literature review
Sign Up to like & getrecommendations! Published in 2024 at "Frontiers in Pharmacology"
DOI: 10.3389/fphar.2024.1323083
Abstract: In the realm of clinical management, Papillary Thyroid Cancer (PTC) stands out as a prevalent thyroid malignancy, characterized by significant metabolic challenges, particularly in the context of carbohydrate metabolism. Recent studies have unveiled promising applications… read more here.
Keywords: cancer; dpp; sglt2 inhibitors; dpp sglt2 ... See more keywords